TBPH — Theravance Biopharma Share News
0.000.00%
Last trade - 00:00- $857.84m
- $495.97m
- $107.46m
Theravance Biopharma hypotension drug fails to meet primary goal (updated)
Theravance Biopharma says hypotension drug failed to meet primary goal
Brief: Theravance Biopharma Inc Announces Results From Study 0170, A Second Phase 3 Study Of Ampreloxetine, In Patients With Symptomatic Neurogenic Orthostatic Hypotension (nOH)
Theravance Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Theravance Biopharma Reports Q4 And Full Year 2021 Results
Theravance Biopharma Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Theravance Biopharma, Inc. Announces Enrollment Of First Patient In Yupelri® Phase 4 Study
U.S. STOCKS ON THE MOVE-Zoom, Walt Disney, Best Buy
Theravance Biopharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Theravance Biopharma Q3 Loss Per Share $0.48
Theravance Biopharma Inc expected to post a loss of 56 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-IronNet, ION Geophysical, Offerpad Solutions
U.S. STOCKS ON THE MOVE-Offerpad Solutions, Leap Therapeutics, Phio Pharmaceuticals
Limited value in Theravance's pipeline after multiple failures- analysts
U.S. RESEARCH ROUNDUP:-Cisco, GXO Logistics, Theravance Biopharma
U.S. STOCKS ON THE MOVE-Nuwellis, Kaival Brands, GreenSky
U.S. STOCKS ON THE MOVE-Sonim Technologies, Casinos, GreenSky
Theravance plunges on blood pressure drug failure, headcount reduction
U.S. STOCKS ON THE MOVE-Sonim Technologies, Avalo, Microsoft